ngram

🌟 GLP-1 Drugs Set to Dominate Pharma Industry in 2024 🌟 GLP-1 drugs, such as Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, have surged in popularity and are poised to revolutionize the pharmaceutical landscape. Key Highlights from GlobalData Plc: > Market Leadership: GLP-1s are expected to become the best-selling drug class in 2024, surpassing PD-1 inhibitors. > Sales Projections: 2024: Nearly $50 billion in annual sales for GLP-1s. 2029: Forecasted to exceed $100 billion in annual sales. > Growth Rate: GLP-1s are projected to grow at a CAGR of 19.2% over the next five years, compared to 4.7% for PD-1 inhibitors. > Industry Shift: Reflects a shift in demand from oncology to metabolic disorder treatments. Insights from GlobalData Analyst Kevin Marcaida: 1️⃣ "This shift could reflect a changing demand away from oncology toward addressing metabolic disorders." 2️⃣ "As industry leaders such as Novo Nordisk and Eli Lilly drive this evolution, GlobalData anticipates a reorientation in drug preferences in the coming years.” #GLP1 #GLP1AgonistDrugMarket #PharmaMarketLandscape #PharmaMarket #PharmaIndustry #Pharma

In 2023, the Oncology therapeutic area dominated completed clinical trial activity, significantly outpacing other areas. Central nervous system trials regained the third position after being temporarily surpassed by infectious diseases during the COVID-19 pandemic years of 2021 and 2022. Other therapeutic areas of note with completed trials in 2023 were: ➡️ Cardiovascular: 358 ➡️ Vaccines: 286 ➡️ Ophthalmology: 136 ➡️ Genitourinary: 62 #clinicaltrials #clinicaltrialactivity #clinicaltrialupdates #competitiveintelligence

#Pharma folks, see you at the polls today! #GLP1 #GLP1Agonists

The time to take action is now. #WorldNoTobaccoDay

Quick industry overview, #pharma professionals. 👇🏽 The global lung cancer liquid biopsy market was valued at approximately USD 0.98 billion in 2023 and is expected to reach around USD 3.43 billion by 2033. Key Insights: 👉🏽 In 2023, North America dominated the global market, holding a 51% share. 👉🏽 The hospitals and laboratories segment accounted for the largest market share by end-use in 2023. 👉🏽 Specialty clinics are expected to have the fastest CAGR from 2024 to 2033 among end-use segments. 👉🏽 The circulating nucleic acids segment was the leading contributor to the market share by biomarker in 2023. 👉🏽 The multi-gene parallel analysis (NGS) segment achieved the highest revenue share by technology in 2023 and is anticipated to grow at the fastest CAGR from 2024 to 2033. 👉🏽 In terms of clinical application, the therapy selection segment secured the largest market share in 2023. 👉🏽 The instruments segment held the largest revenue share by product in 2023 and is projected to register the fastest CAGR during the forecast period. To access the report, click here: https://lnkd.in/gcFTa3iB #pharmainsights #pharmaupdates #pharmaindustry

#Pharma folks, it's time for a quick Monday regulatory check-in!

💊 The global oncology drugs market sector, valued at over $200 billion, remains the largest and most dynamic. Here’s an overview of the top oncology drugs and key insights: 1️⃣ Keytruda (pembrolizumab) from Merck remained the top-selling cancer drug in 2023 with sales of $25 billion, a 19% increase from 2022. 2️⃣ Darzalex (daratumumab) from Johnson & Johnson was the second best-selling cancer drug in 2023 with sales of $9.744 billion, a 22% increase from the previous year. 3️⃣ Opdivo (nivolumab) from Bristol Myers Squibb was the third best-selling cancer drug with sales around $9-9.3 billion in 2023, representing growth of 9-10% compared to 2022. 4️⃣ Revlimid (lenalidomide) from Bristol Myers Squibb saw a significant sales decline in 2023 to around $6 billion, down from over $10 billion in 2022, due to generic erosion. While drugs targeting solid tumours appear to be dominating the list, Darzalex, Revlimid, Imbruvica rank high in the list signifying the high unmet need with the hematologic malignancies. It is also interesting to see equal numbers small molecules to mAbs on the top 10 list. The coming years promise major changes, with notable LOEs*, advancements in ADCs, and favorable capital markets, ensuring oncology remains a vibrant sector in biopharma. *Top sellers like Pfizer's Ibrance (2027), Merck's Keytruda, and BMS's Opdivo (2028) are approaching loss of exclusivity. #PharmaMarket #GlobalPharma #Oncology #OncologyMarket #OncologyDrugs #OncologyDrugMarket

🚨 Generative AI is top-of-mind for most pharma companies, with 75% citing it as a C-suite and board priority. 💰 Budget Integration: 40% of pharmaceutical executives are including AI-driven savings in their 2024 budgets, reflecting high confidence in the technology's potential. 🔍 Focus on IT and Research: IT and research remain the top areas for generative AI investment, with over 60% of executives having at least a proof of concept in development. 💡 Swift Implementation: Early adopters have achieved significant progress, often developing a working pilot within eight weeks, resulting in notable productivity enhancements and cost reductions. So what are the key strategies for scaling Gen AI in Pharma? ✅ Partnering with technology firms and academic institutions to leverage diverse expertise and resources. ✅ Prioritizing data integrity and robust data management systems to derive meaningful insights. ✅ Buildinging multidisciplinary teams comprising data scientists and domain experts. ✅ Integrating ethical considerations to safeguard against biases and ensure patient privacy. ✅ Utilizing agile methodologies to iterate, learn, and adapt swiftly. As a pharma professional, how do you perceive the integration of generative AI into your budgets? Share your insights in the comments, we'd love to know 👇🏽 #GenerativeAI #Pharma #Innovation #AIinPharma #GenerativeAIinPharma

Any guesses, #Pharma community?

🔔 Enabling comprehensive and timely research: everything we do is a step in that direction. That’s why we’re thrilled about nGram alerts! We know how frustrating it can be to miss out on crucial competitor updates. With nGram alerts, you get daily, timely updates delivered right to your inbox. Plus, our alerts highlight the most important, actionable insights for you! ✨ If you're looking for the latest in #Oncology, sign up now! ✅ https://lnkd.in/dU7rXasF #AIinnovation #CompetitiveIntelligence #CompetitorAlerts #Oncology